Cassava Sciences Inc. [NASDAQ: SAVA] stock went on an upward path that rose over 28.42% on Tuesday, amounting to a one-week price increase of more than 26.04%. The company report on September 8, 2022 that Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held in New York.
Remi Barbier, President & CEO, will participate in-person at this corporate event. Institutional investors who are registered for this conference may log into www.hcwevents.com to request a meeting with Cassava Sciences, pending availability.
Over the last 12 months, SAVA stock dropped by -19.37%. The one-year Cassava Sciences Inc. stock forecast points to a potential upside of 43.61. The average equity rating for SAVA stock is currently 2.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.59 billion, with 40.02 million shares outstanding and 37.38 million shares in the current float. Compared to the average trading volume of 2.59M shares, SAVA stock reached a trading volume of 7347512 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Cassava Sciences Inc. [SAVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SAVA shares is $69.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SAVA stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Cassava Sciences Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 15, 2021. While these analysts kept the previous recommendation, Maxim Group dropped their target price from $80 to $190. The new note on the price target was released on July 07, 2021, representing the official price target for Cassava Sciences Inc. stock. Previously, the target price had yet another raise to $78, while B. Riley Securities analysts kept a Buy rating on SAVA stock. On February 16, 2021, analysts increased their price target for SAVA shares from 20 to 66.
The Average True Range (ATR) for Cassava Sciences Inc. is set at 3.56 The Price to Book ratio for the last quarter was 7.13, with the Price to Cash per share for the same quarter was set at 4.83.
SAVA Stock Performance Analysis:
Cassava Sciences Inc. [SAVA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 26.04. With this latest performance, SAVA shares gained by 52.11% in over the last four-week period, additionally plugging by 1.81% over the last 6 months – not to mention a drop of -19.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SAVA stock in for the last two-week period is set at 71.65, with the RSI for the last a single of trading hit 75.16, and the three-weeks RSI is set at 68.39 for Cassava Sciences Inc. [SAVA]. The present Moving Average for the last 50 days of trading for this stock 24.56, while it was recorded at 32.95 for the last single week of trading, and 32.31 for the last 200 days.
Insight into Cassava Sciences Inc. Fundamentals:
Return on Equity for this stock declined to -18.71, with Return on Assets sitting at -17.94.
Cassava Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 23.40 and a Current Ratio set at 23.40.
Cassava Sciences Inc. [SAVA] Insider Position Details
There are presently around $389 million, or 25.30% of SAVA stock, in the hands of institutional investors. The top three institutional holders of SAVA stocks are: BLACKROCK INC. with ownership of 2,661,720, which is approximately -1.559% of the company’s market cap and around 4.70% of the total institutional ownership; VANGUARD GROUP INC, holding 2,047,712 shares of the stock with an approximate value of $79.68 million in SAVA stocks shares; and STATE STREET CORP, currently with $38.91 million in SAVA stock with ownership of nearly -5.113% of the company’s market capitalization.
Positions in Cassava Sciences Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 56 institutional holders increased their position in Cassava Sciences Inc. [NASDAQ:SAVA] by around 1,078,339 shares. Additionally, 84 investors decreased positions by around 1,311,400 shares, while 39 investors held positions by with 7,600,050 shares. The mentioned changes placed institutional holdings at 9,989,789 shares, according to the latest SEC report filing. SAVA stock had 17 new institutional investments in for a total of 417,534 shares, while 31 institutional investors sold positions of 339,039 shares during the same period.